<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568034</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-201</org_study_id>
    <secondary_id>2008-003869-72</secondary_id>
    <nct_id>NCT01568034</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067 on the Levodopa Pharmacokinetics, Motor Response, and Erythrocyte Soluble Catechol-O-methyltransferase Activity in Parkinson's Disease Patients Concomitantly Treated With Levodopa/Dopa-decarboxylase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of BIA 9-1067 on the levodopa
      pharmacokinetics when administered in combination with immediate release levodopa/carbidopa
      or levodopa/benserazide in Parkinson's Disease (PD) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a three-centre, double-blind, randomised, placebo-controlled, crossover study with
      four consecutive single-dose treatment periods in PD patients treated with immediate release
      100 mg/25 mg levodopa/carbidopa or 100 mg/25 mg levodopa/benserazide
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Plasma Concentration Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>Cmax - Maximum plasma concentration (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax = Time to Cmax Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>tmax = time to Cmax (values are median)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-6 - Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours Post-dose (Day 3)</measure>
    <time_frame>Day 3</time_frame>
    <description>AUC0-6 - area under the plasma concentration-time curve from time 0 to 6 hours post-dose (ng.h/mL)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Sequence A Period 1 - 25 mg BIA 9-1067 Period 2 - 50 mg BIA 9-1067 Period 3 - 100 mg BIA 9-1067 Period 4 - Placebo
Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Sequence B Period 1 - Placebo Period 2 - 25 mg BIA 9-1067 Period 3 - 50 mg BIA 9-1067 Period 4 - 100 mg BIA 9-1067
Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Sequence C Period 1 - 100 mg BIA 9-1067 Period 2 - Placebo Period 3 - 25 mg BIA 9-1067 Period 4 - 50 mg BIA 9-1067
Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Sequence D Period 1 - 50 mg BIA 9-1067 Period 2 - 100 mg BIA 9-1067 Period 3 - Placebo Period 4 - 25 mg BIA 9-1067
Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <description>BIA 9-1067 - 25 mg single-dose</description>
    <arm_group_label>Treatment Sequence A</arm_group_label>
    <arm_group_label>Treatment Sequence B</arm_group_label>
    <arm_group_label>Treatment Sequence C</arm_group_label>
    <arm_group_label>Treatment Sequence D</arm_group_label>
    <other_name>OPC, Opicapone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <description>BIA 9-1067 - 50 mg single-dose</description>
    <arm_group_label>Treatment Sequence A</arm_group_label>
    <arm_group_label>Treatment Sequence B</arm_group_label>
    <arm_group_label>Treatment Sequence C</arm_group_label>
    <arm_group_label>Treatment Sequence D</arm_group_label>
    <other_name>OPC, Opicapone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <description>BIA 9-1067 - 100 mg single-dose</description>
    <arm_group_label>Treatment Sequence A</arm_group_label>
    <arm_group_label>Treatment Sequence B</arm_group_label>
    <arm_group_label>Treatment Sequence C</arm_group_label>
    <arm_group_label>Treatment Sequence D</arm_group_label>
    <other_name>OPC, Opicapone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single-dose</description>
    <arm_group_label>Treatment Sequence A</arm_group_label>
    <arm_group_label>Treatment Sequence B</arm_group_label>
    <arm_group_label>Treatment Sequence C</arm_group_label>
    <arm_group_label>Treatment Sequence D</arm_group_label>
    <other_name>PLC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa/Carbidopa</intervention_name>
    <description>Levodopa 100 mg Carbidopa 25 mg</description>
    <arm_group_label>Treatment Sequence A</arm_group_label>
    <arm_group_label>Treatment Sequence B</arm_group_label>
    <arm_group_label>Treatment Sequence C</arm_group_label>
    <arm_group_label>Treatment Sequence D</arm_group_label>
    <other_name>Sinemet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa/Benzerazide</intervention_name>
    <description>Levodopa 100 mg Benzerazide 25 mg</description>
    <arm_group_label>Treatment Sequence A</arm_group_label>
    <arm_group_label>Treatment Sequence B</arm_group_label>
    <arm_group_label>Treatment Sequence C</arm_group_label>
    <arm_group_label>Treatment Sequence D</arm_group_label>
    <other_name>Madopar®/Restex®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female of non-childbearing potential (by reason of surgery or postmenopausal);

          -  Aged between 30 and 75 years, inclusive;

          -  A diagnosis of PD according to the UK PDS Brain Bank diagnostic criteria (bradykinesia
             and at least one of the following: muscular rigidity, rest tremor and postural
             instability);

          -  Predictable signs of end-of-dose deterioration despite &quot;optimal&quot; levodopa/carbidopa or
             levodopa/benserazide therapy;

          -  Been treated with a stable regimen of 3 to 8 doses of standard release 100 mg/25 mg
             levodopa/carbidopa or 100 mg/25 mg levodopa/benserazide per day within at least 1 week
             prior to randomisation;

          -  Modified Hoehn and Yahr stage of less than 5 in the off-state;

          -  Mean duration of OFF stage ≥ 1.5 h during waking hours (based on historical
             information);

          -  Concomitant anti-Parkinsonian medication (other than apomorphine, entacapone or
             tolcapone) in stable doses for at least 4 weeks prior to randomisation;

          -  Results of clinical laboratory tests acceptable by the investigator (not clinically
             significant for the well-being of the subject or for the purpose of the study);

          -  Able and willing to give written informed consent.

        Exclusion Criteria:

          -  Non-idiopathic parkinsonism (atypical parkinsonism, symptomatic parkinsonism,
             Parkinson-plus syndrome);

          -  Treated with levodopa/carbidopa or levodopa/benserazide in a 10:1 ratio, or with
             levodopa/carbidopa in a controlled-release formulation;

          -  Treated with entacapone, tolcapone, neuroleptics, antidepressants (except
             serotonin-specific reuptake inhibitors or imipramines [desipramine, imipramine,
             clomipramine and amitriptyline]), monoamine oxidase inhibitors (except selegiline up
             to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation or
             rasagiline up to 1 mg/day) or antiemetics (except domperidone) within 4 weeks prior to
             randomisation;

          -  Treated with apomorphine within 7 days prior to randomisation;

          -  Treated with any investigational product within 2 months prior to randomisation (or
             within 5 half-lives, whichever is longer);

          -  A psychiatric or any medical condition that might place him/her at increased risk or
             interfere with assessments;

          -  Known hypersensitivity to any of the ingredients of the investigational products;

          -  A history of abuse of alcohol, drugs or medications within the last 2 years;

          -  A clinically relevant ECG abnormality;

          -  A history or current evidence of heart disease, including but not limited to
             myocardial infarction, angina, congestive heart failure and cardiac arrhythmia;

          -  Unstable concomitant disease being treated with changing doses of medication;

          -  A history or current evidence of any relevant disease in the context of this study,
             i.e., with respect to the safety of the subject (e.g., hepatic or renal impairment) or
             related to the study conditions;

          -  A test positive for the human immunodeficiency viruses (HIV) 1 or 2 antibodies, or
             hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb);

          -  Donated blood or received blood or blood products within the 6 months prior to
             randomisation;

          -  Pregnant, breast-feeding or of childbearing potential;

          -  Other condition or circumstance that, in the opinion of the investigator, may
             compromise the subject's ability to comply with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquim Ferreira, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Santa Maria - Lisbon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology-Hospital de Santa Maria-Faculty of Medicine, University of Lisbon</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Colentina - Clinica de Neurologie</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology- Hospital of the department of medical care of Ministry Internal Affairs of Ukraine</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <results_first_submitted>February 5, 2014</results_first_submitted>
  <results_first_submitted_qc>December 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 12, 2015</results_first_posted>
  <last_update_submitted>December 19, 2014</last_update_submitted>
  <last_update_submitted_qc>December 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>BIA 9-1067</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Opicapone</mesh_term>
    <mesh_term>Aromatic Amino Acid Decarboxylase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence A</title>
          <description>Period 1 - 25 mg BIA 9-1067 Period 2 - 50 mg BIA 9-1067 Period 3 - 100 mg BIA 9-1067 Period 4 - Placebo
Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence B</title>
          <description>Treatment Sequence B Period 1 - Placebo Period 2 - 25 mg BIA 9-1067 Period 3 - 50 mg BIA 9-1067 Period 4 - 100 mg BIA 9-1067
Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half</description>
        </group>
        <group group_id="P3">
          <title>Treatment Sequence C</title>
          <description>Treatment Sequence C Period 1 - 100 mg BIA 9-1067 Period 2 - Placebo Period 3 - 25 mg BIA 9-1067 Period 4 - 50 mg BIA 9-1067
Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half</description>
        </group>
        <group group_id="P4">
          <title>Treatment Sequence D</title>
          <description>Treatment Sequence D Period 1 - 50 mg BIA 9-1067 Period 2 - 100 mg BIA 9-1067 Period 3 - Placebo Period 4 - 25 mg BIA 9-1067
Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>25 mg BIA 9-1067</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>50 mg BIA 9-1067</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>100 mg BIA 9-1067</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>The study was to consist of four consecutive treatment periods, corresponding to the 4 different treatment options (25 mg, 50 mg and 100 mg BIA 9-1067or Placebo).According to randomisation, subjects were to receive, in a double-blind manner, 25, 50 and 100 mg BIA 9-1067 or Placebo at 4 separate treatment periods. Each subject were to receive each of the three BIA 9-1067 doses and Placebo in a random sequence with a 3:1 ratio (BIA 9-1067: Placebo) per treatment period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Plasma Concentration Day 3</title>
        <description>Cmax - Maximum plasma concentration (ng/mL)</description>
        <time_frame>Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>PLC, Placebo</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 25 mg</title>
            <description>BIA 9-1067 - OPC, Opicapone</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg</title>
            <description>BIA 9-1067 - OPC, Opicapone</description>
          </group>
          <group group_id="O4">
            <title>BIA 9-1067 100 mg</title>
            <description>BIA 9-1067 - OPC, Opicapone</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Plasma Concentration Day 3</title>
          <description>Cmax - Maximum plasma concentration (ng/mL)</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax (levodopa)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2103" spread="48.4"/>
                    <measurement group_id="O2" value="2112" spread="49.6"/>
                    <measurement group_id="O3" value="2366" spread="44.0"/>
                    <measurement group_id="O4" value="2657" spread="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (3-OMD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3996" spread="50.5"/>
                    <measurement group_id="O2" value="4193" spread="42.4"/>
                    <measurement group_id="O3" value="4284" spread="49.2"/>
                    <measurement group_id="O4" value="4085" spread="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (BIA 9-067)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">BIA 9-067 was not administered</measurement>
                    <measurement group_id="O2" value="320" spread="57.2"/>
                    <measurement group_id="O3" value="590" spread="41.5"/>
                    <measurement group_id="O4" value="816" spread="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-6 - Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours Post-dose (Day 3)</title>
        <description>AUC0-6 - area under the plasma concentration-time curve from time 0 to 6 hours post-dose (ng.h/mL)</description>
        <time_frame>Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>PLC, Placebo</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 25 mg</title>
            <description>BIA 9-1067 - OPC, Opicapone</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg</title>
            <description>BIA 9-1067 - OPC, Opicapone</description>
          </group>
          <group group_id="O4">
            <title>BIA 9-1067 100 mg</title>
            <description>BIA 9-1067 - OPC, Opicapone</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-6 - Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours Post-dose (Day 3)</title>
          <description>AUC0-6 - area under the plasma concentration-time curve from time 0 to 6 hours post-dose (ng.h/mL)</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-6 (levodopa)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3958" spread="46.7"/>
                    <measurement group_id="O2" value="4545" spread="61.4"/>
                    <measurement group_id="O3" value="4580" spread="36.5"/>
                    <measurement group_id="O4" value="5440" spread="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-6 (3-OMD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22334" spread="51.1"/>
                    <measurement group_id="O2" value="22026" spread="44.3"/>
                    <measurement group_id="O3" value="23515" spread="50.0"/>
                    <measurement group_id="O4" value="22200" spread="61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-6 (BIA 9-1067)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">BIA 9-067 was not administered</measurement>
                    <measurement group_id="O2" value="776" spread="60.1"/>
                    <measurement group_id="O3" value="1694" spread="34.6"/>
                    <measurement group_id="O4" value="2647" spread="51.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax = Time to Cmax Day 3</title>
        <description>tmax = time to Cmax (values are median)</description>
        <time_frame>Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>PLC, Placebo</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 25 mg</title>
            <description>BIA 9-1067 - OPC, Opicapone</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg</title>
            <description>BIA 9-1067 - OPC, Opicapone</description>
          </group>
          <group group_id="O4">
            <title>BIA 9-1067 100 mg</title>
            <description>BIA 9-1067 - OPC, Opicapone</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax = Time to Cmax Day 3</title>
          <description>tmax = time to Cmax (values are median)</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax (levodopa)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.5" upper_limit="1.5"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.5" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax (3-OMD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.75" lower_limit="0.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="2.50" lower_limit="0.0" upper_limit="4.0"/>
                    <measurement group_id="O4" value="1.75" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax (BIA 9-067)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">BIA 9-067 was not administered</measurement>
                    <measurement group_id="O2" value="2.00" lower_limit="0.5" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>25 mg BIA 9-1067</title>
          <description>25 mg BIA 9-1067 ESL, Eslicarbazepine</description>
        </group>
        <group group_id="E2">
          <title>50 mg BIA 9-1067</title>
          <description>50 mg BIA 9-1067 ESL, Eslicarbazepine</description>
        </group>
        <group group_id="E3">
          <title>100 mg BIA 9-1067</title>
          <description>100 mg BIA 9-1067 ESL, Eslicarbazepine</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo ESL, Eslicarbazepine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>RESPIRATORY INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>EOSINOPHIL PERCENTAGE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>LIGHTHEADEDNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>PALLOR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>BIAL – Portela &amp; Cª S.A.</organization>
      <phone>+351-229866100</phone>
      <email>clinical.trials@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

